B cell chronic lymphocytic leukemia: Lessons learned from studies of the B cell antigen receptor

Annual Review of Immunology

Volumn 21, Issue , 2003, Pages 841-894

  Chiorazzi, Nicholas ^a,b   Ferrarini, Manlio ^c  

^a N Shore Long Isl Jewish Res Inst ^*  (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Antibody repertoire; Ig V gene; Lymphocyte subsets; Lymphoma; Somatic hypermutation

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; B CELL ANTIGEN RECEPTOR; B LYMPHOCYTE ANTIGEN; CASPASE 3; CASPASE 8; CASPASE 9; CD38 ANTIGEN; CD40 ANTIGEN; CYCLIN D2; CYTOCHROME C; FAS ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; IMMUNOGLOBULIN V; LYMPHOCYTE ANTIGEN RECEPTOR; NUCLEAR FACTOR; PROTEIN BCL 6; TELOMERASE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; B CELL LEUKEMIA; CELL CLONING; CELL DIFFERENTIATION; CELL MATURATION; CELL SURFACE; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME 3Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CROSS LINKING; CYTOGENETICS; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; LEUKEMIA CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CLONE; LYMPHOCYTE SUBPOPULATION; MOLECULAR BIOLOGY; MULTIGENE FAMILY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TELOMERE; TRISOMY 12; B LYMPHOCYTE; BIOLOGICAL MODEL; CELL CLONE; GENETICS; IMMUNOGLOBULIN GENE; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PRELEUKEMIA;

APOPTOSIS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CLONE CELLS; GENES, IMMUNOGLOBULIN; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; MUTATION; PRELEUKEMIA; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 0042971643     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.21.120601.141018     Document Type: Review

References (285)

1. Rai KR, Patel DV. 1995. Chronic lymphocytic leukemia. In Hematology: Basic Principles and Practice, ed. R Hoffman, E Benz, S Shattil, B Furie, H Cohen, L Silberstein, pp. 1308-21. New York: Churchill Livingstone. 2nd ed.
2. Rozman C, Montserrat E. 1995. Chronic lymphocytic leukemia. N. Engl. J. Med. 333:1052-57
3. Batata A, Shen B. 1992. Immunophenotyping of subtypes of B-chronic (mature) lymphoid leukemia. A study of 242 cases. Cancer 70:2436-43
4. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, et al. 1994. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-45
5. Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, et al. 1997. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am. J. Clin. Pathol. 108:378-82
6. Dameshek W. 1967. Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood 29(Suppl.):566-84
7. Kuppers R, Dalla-Favera R. 2001. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580-94
8. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, et al. 1998. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102:1515-25
9. Chiorazzi N, Ferrarini M. 2001. Immunoglobulin variable region gene characteristics and surface membrane phenotype define B-CLL subgroups with distinct clinical courses. See Ref. 277, pp. 81-109
10. Schroeder HW Jr, Dighiero G. 1994. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol. Today 15:288-94
11. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. 1999. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-54
12. Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, et al. 2002. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99:2262-64
13. Johnson TA, Rassenti LZ, Kipps TJ. 1997. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J. Immunol. 158:235-46
14. Rassenti LZ, Kipps TJ. 1997. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J. Exp. Med. 185:1435-45
15. Ghiotto F, Fais F, Albesiano E, Gaidano G, Allen SL, et al. 2002. The light chain variable region gene repertoire of chronic lymphocytic leukemia B cells. In preparation
16. Yancopoulos GD, Desiderio SV, Paskind M, Kearney JF, Baltimore D, Alt FW. 1984. Preferential utilization of the most JH-proximal VH gene segments in pre-B-cell lines. Nature 311:727-33
17. Perlmutter RM, Kearney JF, Chang SP, Hood LE. 1985. Developmentally controlled expression of immunoglobulin VH genes. Science 227:1597-601
18. Schroeder HW Jr, Hillson JL, Perlmutter RM. 1987. Early restriction of the human antibody repertoire. Science 238:791-93
19. Suzuki I, PfisterL, Glas A, Nottenburg C, Milner EC. 1995. Representation of rearranged VII gene segments in the human adult antibody repertoire. J. Immunol. 154:3902-11
20. Hillson JL, Oppliger IR, Sasso EH, Milner EC, Wener MH. 1992. Emerging human B cell repertoire. Influence of developmental stage and interindividual variation. J. Immunol. 149:3741-52
21. Kraj P, Rao SP, Glas AM, Hardy RR, Milner EC, Silberstein LE. 1997. The human heavy chain Ig V region gene repertoire is biased at all stages of B cell ontogeny, including early pre-B cells. J. Immunol. 158:5824-32
22. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD. 1994. Analysis of somatic mutation in five B cell subsets of human tonsil. J. Exp. Med. 180:329-39
23. Brezinschek HP, Foster SJ, Brezinschek RI, Dorner T, Domiati-Saad R, Lipsky PE. 1997. Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J. Clin. Invest. 99:2488-501
24. Gay D, Saunders T, Camper S, Weigert M. 1993. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177:999-1008
25. Radic MZ, Erikson J, Litwin S, Weigert M. 1993. B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 177:1165-73
26. Tiegs SL, Russell DM, Nemazee D. 1993. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177:1009-20
27. Chen C, Nagy Z, Prak EL, Weigert M. 1995. Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing. Immunity 3:747-55
28. Wilson PC, Wilson K, Liu Y-J, Banchereau J, Pascual V, Capra ID. 2000. Receptor revision of immunoglobulin heavy chain variable region genes in normal human B lymphocytes. J. Exp. Med. 191:1881-94
29. Nemazee D, Weigert M. 2000. Revising B cell receptors. J. Exp. Med. 191:1813-17
30. Stall AM, Farinas MC, Tarlinton DM, Lalor PA, Herzenberg LA, et al. 1988. Ly-1 B-cell clones similar to human chronic lymphocytic leukemias routinely develop in older normal mice and young autoimmune (New Zealand Black-related) animals. Proc. Natl. Acad. Sci. USA 85:7312-16
31. Viale AC, Chies JA, Huetz F, Malenchere E, Weksler M, et al. 1994. VH-gene family dominance in ageing mice. Scand. J. Immunol. 39:184-88
32. Radl J. 1990. Age-related monoclonal gammapathies: clinical lessons from the aging C57BL mouse. Immunol. Today 11:234-36
33. van den Akker TW, Brondijk R, Radl J. 1988. Influence of long-term antigenic stimulation started in young C57BL mice on the development of age-related monoclonal gammapathies. Int. Arch. Allergy Appl. Immunol. 87:165-70
34. van Arkel C, Hopstaken CM, Zurcher C, Bos NA, Kroese FG, et al. 1997. Monoclonal gammopathies iri aging mu, kappa-transgenic mice: involvement of the B-1 cell lineage. Eur. J. Immunol. 27:2436-40
35. Cai J, Humphries C, Richardson A, Tucker PW. 1992. Extensive and selective mutation of a rearranged VH5 gene in human B cell chronic lymphocytic leukemia. J. Exp. Med. 176:1073-81
36. Hashimoto S, Wakai M, Silver J, Chiorazzi N. 1992. Biased usage of variable and constant-region Ig genes by IgG+, CD5+ human leukemic B cells. Ann. NY Acad. Sci. 651:477-79
37. Hashimoto S, Dono M, Wakai M, Allen SL, Lichtman SM, et al. 1995. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells. J. Exp. Med. 181:1507-17
38. Oscier DG, Thompsett A, Zhu D, Stevenson FK. 1997. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 89:4153-60
39. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, et al. 2002. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-16
40. Jukes TH, King JL. 1979. Evolutionary nucleotide replacements in DNA. Nature 281:605-6
41. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, Weigert MG. 1987. The role of clonal selection and somatic mutation in autoimmunity. Nature 328:805-11
42. Klein U, Rajewsky K, Kuppers R. 1998. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188:1679-89
43. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, et al. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-47
44. Tonegawa S. 1983. Somatic generation of antibody diversity. Nature 302:575-81
45. Sanz I. 1991. Multiple mechanisms participate in the generation of diversity of human H chain CDR3 regions. J. Immunol. 147:1720-29
46. Corbett SJ, Tomlinson IM, Sonnhammer ELL, Buck D, Winter G. 1997. Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination. J. Mol. Biol. 270:587-97
47. Raaphorst FM, Raman CS, Tami J, Fischbach M, Sanz I. 1997. Human Ig heavy chain CDR3 regions in adult bone marrow pre-B cells display an adult phenotype of diversity: evidence for structural selection of DH amino acid sequences. Int. Immunol. 9:1503-15
48. Valetto A, Ghiotto F, Fais F, Hashimoto S, Allen SL, et al. 1998. A subset of IgG+ B-CLL cells expresses virtually identical antigen receptors that bind similar peptides. Blood 92:A431
49. Wakai M, Hashimoto S, Omata M, Sthoeger ZM, Allen SL, et al. 1994. IgG+, CD5+ human chronic lymphocytic leukemia B cells. Production of IgG antibodies that exhibit diminished autoreactivity and IgG subclass skewing. Autoimmunity 19:39-48
50. Ghiotto F, Fais F, Valetto A, Hashimoto S, Allen SL, et al. 2002. A subset of IgG+ B-CLL cells express antigen receptors with remarkable similarities in Ig V gene use and HCDR3 characteristics. Submitted
51. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat AM, et al. 1995. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85:2870-76
52. Schuh K, Avots A, Tony HP, Serfling E, Kneitz C. 1996. Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk. Lymphoma. 23:583-92
53. Frank DA, Mahajan S, Ritz J. 1997. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest. 100:3140-48
54. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, et al. 2001. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194:1639-47
55. Marti GE, Zenger V, Caproaso NE, Brown M, Washington GC, et al. 1989. Antigenic expression of B-cell chronic lymphocytic leukemic lymphocytes. Anal. Quant. Cytol. Histol. 11:315-23
56. Cerutti A, Trentin L, Zambello R, Sancetta R, Milani A, et al. 1996. The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. J. Immunol. 157:1854-62
57. Trentin L, Zambello R, Sancetta R, Facco M, Cerutti A, et al. 1997. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res. 57:4940-47
58. Schattner EJ, Mascarenhas J, Reyfman I, Koshy M, Woo C, et al. 1998. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 91:2689-97
59. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, et al. 2002. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99:4087-93
60. van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, et al. 1993. Expression and release of CD27 in human B-cell malignancies. Blood 82:3430-36
61. Ranheim EA, Cantwell MJ, Kipps TJ. 1995. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85:3556-65
62. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, et al. 1997. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur. J. Immunol. 27:2073-79
63. Agematsu K, Nagumo H, Shinozaki K, Hokibara S, Yasui K, et al. 1998. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J. Clin. Invest. 102:853-60
64. Hubmann R, Schwarzmeier ID, Shehata M, Hilgarth M, Duechler M, et al. 2002. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 99:3742-27
65. Allsopp RC, Chang E, Kashefi-Aazam M, Rogaev EI, Piatyszek MA, et al. 1995. Telomere shortening is associated with cell division in vitro and in vivo. Exp. Cell Res. 220:194-200
66. Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM. 1998. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat. Biotechnol. 16:743-47
67. Damle R, Batliwala F, Allen SL, Kolitz JE, Vinciguerra VP, et al. 2002. Telomere length and telomerase activity in chronic lymphocytic leukemia B cells. Submitted
68. Morin GB. 1989. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59:521-29
69. Bechter OE, Eisterer W, Pall G, Hilbe W, Kuhr T, Thaler J. 1998. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 58:4918-22
70. Hu BT, Lee SC, Matin E, Ryan DH, Insel RA. 1997. Telomerase is upregulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J. Immunol. 159:1068-71
71. Weng NP, Granger L, Hodes RJ. 1997. Telomere lengthening and telomerase activation during human B cell differentiation. Proc. Natl. Acad. Sci. USA 94:10827-32
72. Norrback KF, Hultdin M, Dahlenborg K, Osterman P, Carlsson R, Roos G. 2001. Telomerase regulation and telomere dynamics in germinal centers. Eur. J. Haematol. 67:309-17
73. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, et al. 2001. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194:1625-38
74. Gauld SB, Dal Porto JM, Cambier JC. 2002. B cell antigen receptor signaling: roles in cell development and disease. Science 296:1641-42
75. Carey GB, Donjerkovic D, Mueller CM, Liu S, Hinshaw JA, et al. 2000. B-cell receptor and Fas-mediated signals for life and death. Immunol. Rev. 176:105-15
76. Zupo S, Massara R, Dono M, Rossi E, Malavasi E et al. 2000. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 95:1199-206
77. Mangiola G, Ferrarini M, Zupo S. 2002. Studies on the BCR signal transduction capacities in various B-CLL subsets. In preparation
78. Mangiola M, Cutrona G, Ferrarini M, Dono M, Colombo M, Zupo S. 2002. Mechanisms of apoptosis in B-CLL cells stimulated via the B cell antigen receptor. In preparation
79. Norvell A, Monroe JG. 1996. Acquisition of surface IgD fails to protect from tolerance-induction. Both surface IgM- and surface IgD-mediated signals induce apoptosis of immature murine B lymphocytes. J. Immunol. 156:1328-32
80. Brink R, Goodnow CC, Crosbie J, Adams J, Eris J, et al. 1992. Immunoglobulin M and D antigen receptors are both capable of mediating B lymphocyte activation, deletion, or anergy after interaction with specific antigen. J. Exp. Med. 176:991-1005
81. Ales-Martinez JE, Warner GL, Scott DW. 1988. Immunoglobulins D and M mediate signals that are qualitatively different in B cells with an immature phenotype. Proc. Natl. Acad. Sci. USA 85:6919-23
82. Tisch R, Roifman CM, Hozumi N. 1988. Functional differences between immunoglobulins M and D expressed on the surface of an immature B-cell line. Proc. Natl. Acad. Sci. USA 85:6914-18
83. Kim KM, Reth M. 1995. Signaling difference between class IgM and IgD antigen receptors. Ann. NY Acad. Sci. 766:81-88
84. Carsetti R, Kohler G, Lamers MC. 1993. A role for immunoglobulin D: interference with tolerance induction. Eur. J. Immunol. 23:168-78
85. Mongini PK, Blessinger C, Posnett DN, Rudich SM. 1989. Membrane IgD and membrane IgM differ in capacity to transduce inhibitory signals within the same human B cell clonal populations. J. Immunol. 143:1565-74
86. McConkey DJ, Aguilar-Santelises M, Hartzell P, Eriksson I, Mellstedt H, et al. 1991. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J. Immunol. 146:1072-76
87. Osorio LM, De Santiago A, Aguilar-Santelises M, Mellstedt H, Jondal M. 1997. CD6 ligation modulates the Bcl2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood 89:2833-41
88. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, et al. 2001. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98:3050-57
89. Zupo S, Cutrona G, Mangiola M, Ferrarini M. 2002. Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. Blood 99:2277-78
90. Igney FH, Krammer PH. 2002. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2:277-88
91. Reed JC, Kitada S, Kim Y, Byrd J. 2002. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin. Oncol. 29:10-24
92. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV. 1995. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 9:1227-32
93. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. 1997. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br. J. Haematol. 97:409-17
94. Chu P, Deforce D, Pedersen IM, Kim Y, Kitada S, et al. 2002. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 99:3854-59
95. Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, et al. 1996. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 88:1365-74
96. Roncella S, Cutrona G, Favre A, Ulivi M, Fais F, et al. 1996. Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome. Blood 88:599-608
97. Panayiotidis P, Ganeshaguru K, Jabbar SA, Hoffbrand AV. 1993. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. 85:439-45
98. Pu QQ, Bezwoda WR. 1997. Interleukin-4 prevents spontaneous in-vitro apoptosis in chronic lymphatic leukaemia but sensitizes B-CLL cells to melphalan cytotoxicity. Br. J. Haematol. 98:413-17
99. Chaouchi N, Wallon C, Goujard C, Tertian G, Rudent A, et al. 1996. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 87:1022-29
100. Trentin L, Cerutti A, Zambello R, Sancretta R, Tassinari C, et al. 1996. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 87:3327-35
101. Francia di Celle P, Mariani S, Riera L, Stacchini A, Reato G, Foa R. 1996. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 87:4382-89
102. Malisan F, Fluckiger AC, Ho S, Guret C, Banchereau J, Martinez-Valdez H. 1996. B-chronic lymphocytic leukemias can undergo isotype switching in vivo and can be induced to differentiate and switch in vitro. Blood 87:717-24
103. Pizzolo G, Chilosi M, Ambrosetti A, Semenzato G, Fiore-Donati L, Perona G. 1983. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood 62:1289-96
104. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, et al. 2001. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97:2777-83
105. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. 1996. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. 92:97-103
106. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. 2002. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 99:1030-37
107. Hanada M, Delia D, Aiello A, Stadtmauer, Reed EJ. 1993. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820-26
108. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, et al. 1998. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91:3379-89
109. Schena M, Larsson LG, Gottardi D, Gaidano G, Carlsson M, et al. 1992. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79:2981-89
110. Capello D, Fais F, Vivenza D, Migliaretti G, Chiorazzi N, et al. 2000. Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. Leukemia 14:811-15
111. Capello D, Vitolo U, Pasqualucci L, Quattrone S, Migliaretti G, et al. 2000. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 95:651-59
112. Pasqualucci L, Neri A, Baldini L, Dalla-Favera R, Migliazza A. 2000. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 60:5644-48
113. Pasqualucci L, Migliazza A, Fracchiolla N, William C, Neri A, et al. 1998. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl. Acad. Sci. USA 95:11816-21
114. Shen HM, Peters A, Baron B, Zhu X, Storb U. 1998. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280:1750-52
115. Sahota SS, Davis Z, Hamblin TJ, Stevenson FK. 2000. Somatic mutation of bcl-6 genes can occur in the absence of V(H) mutations in chronic lymphocytic leukemia. Blood 95:3534-40
116. Thunberg U, Johnson A, Roos G, Thorn I, Tobin G, et al. 2001. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 97:1892-94
117. Matrai Z, Lin K, Dennis M, Sherrington P, Zuzel M, et al. JC. 2001. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood 97:1902-3
118. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, et al. 2002. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-29
119. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. 2002. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100:1404-9
120. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, et al. 2002. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. In press
121. Hivroz C, Geny B, Brouet JC, Grillot-Courvalin C. 1990. Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C. J. Immunol. 144:2351-58
122. Michel F, Merle-Beral H, Legac E, Michel A, Debre P, Bismuth G. 1993. Defective calcium response in B-chronic lymphocytic leukemia cells. Alteration of early protein tyrosine phosphorylation and of the mechanism responsible for cell calcium influx. J. Immunol. 150:3624-33
123. Lankester AC, van Schijndel GM, van der Schoot CE, van Oers MH, van Noesel CJ, van Lier RA. 1995. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood 86:1090-71
124. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson FK, Packham G. 2002. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 26:26
125. Lund FE, Yu N, Kim KM, Reth M, Howard MC. 1996. Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression. J. Immunol. 157:1455-67
126. Zupo S, Rugari E, Dono M, Taborelli G, Malavasi F, Ferrarini M. 1994. CD38 signalling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells. Eur. J. Immunol. 24:1218-22
127. Funaro A, Morra M, Calosso L, Zini MG, Ausiello CM, Malavasi F. 1997. Role of the human CD38 molecule in B cell activation and proliferation. Tissue Antigens 49:7-15
128. Alfarano A, Indraccolo S, Circosta P, Minuzzo S, Vallario A, et al. 1999. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 93:2327-35
129. Payelle-Brogard B, Magnac C, Alcover A, Roux P, Dighiero G. 2002. Defective assembly of the B-cell receptor chains accounts for its low expression in B-chronic lymphocytic leukaemia. Br. J. Haematol. 118:976-85
130. Juliusson G, Merup M. 1998. Cytogenetics in chronic lymphocytic leukemia. Semin. Oncol. 25:19-26
131. Oscier DG. 1994. Cytogenetic and mole-cular abnormalities in chronic lymphocytic leukaemia. Blood Rev. 8:88-97
132. Stilgenbauer S, Lichter P, Dohner H. 2001. Genomic aberrations in B cell chronic lymphocytic leukemia. See Ref. 277, pp. 353-76
133. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343:1910-16
134. Karhu R, Knuutila S, Kallioniemi OP, Siltonen S, Aine R, et al. 1997. Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: a study by comparative genomic hybridization. Tampere CLL Group. Genes Chromosomes Cancer 19:286-90
135. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. 1999. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J. Mol. Med. 77:266-81
136. Bigoni R, Cuneo A, Roberti MG, Bardi A, Rigolin GM, et al. 1997. Chromosome aberrations in atypical chronic lymphocytic leukemia: a cytogenetic and interphase cytogenetic study. Leukemia 11:1933-40
137. Bullrich F, Croce CM. 2001. Molecular biology of chronic lymphocytic leukemia. See Ref. 277, pp. 9-32
138. Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, et al. 2001. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res. 61:2870-77
139. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, et al. 1998. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 58:4552-57
140. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, et al. 1999. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 59:24-27
141. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, et al. 1999. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 353:26-29
142. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. 1999. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94:748-53
143. Taylor AM, Metcalfe JA, Thick J, Mak YF. 1996. Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423-38
144. Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, et al. 1997. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat. Med. 3:1155-59
145. Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, et al. 1997. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat. Genet. 17:96-99
146. Rotman G, Shiloh Y. 1999. ATM: a mediator of multiple responses to genotoxic stress. Oncogene 18:6135-44
147. Khanna KK. 2000. Cancer risk and the ATM gene: a continuing debate. J. Natl. Cancer Inst. 92:795-802
148. Gahrton G, Robert KH, Friberg K, Juliusson G, Biberfeld P, Zech L. 1982. Cytogenetic mapping of the duplicated segment of chromosome 12 in lymphoproliferative disorders. Nature 297:513-14
149. Einhorn S, Burvall K, Juliusson G, Gahrton G, Meeker T. 1989. Molecular analyses of chromosome 12 in chronic lymphocytic leukemia. Leukemia 3:871-74
150. el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, et al. 1993. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-59
151. Reed JC, Kitada S. 2001. Apoptosis disregulation in chronic lymphocytic leukemia. See Ref. 277, pp. 111-26
152. Fu TB, Virgilio L, Narducci MG, Facchiano A, Russo G, Croce CM. 1994. Characterization and localization of the TCL-1 oncogene product. Cancer Res. 54:6297-301
153. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, et al. 2000. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 60:2095-100
154. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, et al. 2002. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci. USA 99:6955-60
155. Sgambati MT, Linet MS, Devesa SS. 2001. Chronic lymphocytic leukemia. Epidemiological, familial and genetic aspects. See Ref. 277, pp. 33-62
156. Horwitz M, Goode EL, Jarvik GP. 1996. Anticipation in familial leukemia. Am. J. Hum. Genet. 59:990-98
157. Yuille MR, Houlston RS, Catovsky D. 1998. Anticipation in familial chronic lymphocytic leukaemia. Leukemia 12:1696-98
158. Ishibe N, Sgambati MT, Fontaine L, Goldin LR, Jain N, et al. 2001. Clinical characteristics of familial B-CLL in the National Cancer Institute Familial Registry. Leuk. Lymphoma 42:99-108
159. Bevan S, Catovsky D, Matutes E, Antunovic P, Auger MJ, et al. 2000. Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. Blood 96:3982-84
160. Payelle-Brogard B, Magnac C, Mauro FR, Mandelli F, Dighiero G. 1999. Analysis of the B-cell receptor B29 (CD79b) gene in familial chronic lymphocytic leukemia. Blood 94:3516-22
161. Pritsch O, Troussard X, Magnac C, Mauro FR, Davi F, et al. 1999. VH gene usage by family members affected with chronic lymphocytic leukaemia. Br. J. Haematol. 107:616-24
162. Sakai A, Marti GE, Caporaso N, Pittaluga S, Touchman JW, et al. 2000. Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL. Blood 95:1413-19
163. Zwiebel JA, Cheson BD. 1998. Chronic lymphocytic leukemia: staging and prognostic factors. Semin. Oncol. 25:42-59
164. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. 1975. Clinical staging of chronic lymphocytic leukemia. Blood 46:219-34
165. Rai KR, Han T. 1990. Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 4:447-56
166. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, et al. 1981. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206
167. Maloum K, Davi F, Merle-Beral H, Pritsch O, Magnac C, et al. 2000. Expression of unmutated VH genes is a detrimental prognotic factor in chronic lymphocytic leukemia. Blood 96:377-79
168. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, et al. 2002. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177-84
169. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, et al. 2001. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98:181-86
170. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, et al. 2001. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98:2633-39
171. Chang CC, Cleveland RP. 2002. Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course. Blood 100:1106
172. Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert R, Fitchett M. 1990. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 76:352-58
173. Fitchett M, Griffiths MJ, Oscier DG, Johnson S, Seabtight M. 1987. Chromosome abnormalities involving band 13q14 in hematologic malignancies.
174. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-11
175. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:1937-47
176. Messmer D, Messmer B, Albesiano E, Damle R, Allen SL, et al. 2002. Direct measurement of B-CLL cell production and turnover in vivo. Blood 100:169a
177. LeMaoult J, Delassus S, Dyall R, Nikolic-Zugic J, Kourilsky P, Weksler ME. 1997. Clonal expansions of B lymphocytes in old mice. J. Immunol. 159:3866-74
178. Deane M, Norton JD. 1991. Immunoglobulin gene 'fingerprinting': an approach to analysis of B lymphoid clonality in lymphoproliferative disorders. Br. J. Haematol. 77:274-81
179. Albesiano E, Ghiotto F, Valetto A, Fais F, Allen SL, et al. 2002. Oligoclonal B cell expansions are common in normal aging adults. In preparation
180. Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, et al. 2002. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 100:635-39
181. Silverman GJ, Goldfien RD, Chen P, Mageed RA, Jefferis R, et al. 1988. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of autoantibodies in humans. J. Clin. Invest. 82:469-75
182. Silverman GJ, Schrohenloher RE, Accavitti MA, Koopman WJ, Carson DA. 1990. Structural characterization of the second major cross-reactive idiotype group of human rheumatoid factors. Association with the VH4 gene family. Arthritis Rheum. 33:1347-60
183. Silberstein LE, Jefferies LC, Goldman J, Friedman D, Moore JS, et al. 1991. Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood 78:2372-86
184. Thompson KM, Sutherland J, Barden G, Melamed MD, Randen I, et al. 1991. Human monoclonal antibodies against blood group antigens preferentially express a VH4-21 variable region gene-associated epitope. Scand. J. Immunol. 34:509-18
185. Pascual V, Victor K, Spellerberg M, Hamblin TJ, Stevenson FK, Capra YD. 1992. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J. Immunol. 149:2337-44
186. Stevenson FK, Longhurst C, Chapman CJ, Ehrenstein M, Spellerberg MB, et al. 1993. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. J. Autoimmun. 6:809-25
187. Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, et al. 2001. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 108:1061-70
188. Silverman GJ, Nayak JV, La Cava A. 1997. B-cell superantigens: molecular and cellular implications. Int. Rev. Immunol. 14:259-90
189. Li Y, Spellerberg MB, Stevenson FK, Capra YD, Potter KN. 1996. The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3. J. Mol. Biol. 256:577-89
190. Silverman GJ. 1997. B-cell superantigens. Immunol. Today 18:379-86
191. Blattner W, Saxinger C, Clark J, Mann D. 1983. Human T-cell leukemia/lymphoma virus-associated lymphoreticular neoplasia in Jamaica. Lancet 2:61-64
192. Clark J, Hahn B, Mann D. 1986. Molecular and immunologic analysis of an HTLV-positive CLL case from Jamaica. Cancer 56:495-99
193. Peterman A, Jerdan M, Staal S, Bender B, Striecher H, et al. 1986. Evidence for HTLV-I associated with mycosis fungoides and B-cell chronic lymphocytic leukemia. Arch. Dermatol. 122:568-71
194. Mann D, DeSantis P, Mark G, Pfeifer A, Newman M, et al. 1987. HTLV-I-associated B-cell CLL: indirect role for retrovirus in leukemogenesis. Science 236:1103-6
195. Casadevall A, Scharff MD. 1991. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J. Exp. Med. 174:151-60
196. Milner EC, Capra JD. 1982. VH families in the antibody response to p-azophenylarsonate: correlation between serology and amino acid sequence. J. Immunol. 129:193-99
197. Jeske DJ, Jarvis J, Milstein C, Capra JD. 1984. Junctional diversity is essential to antibody activity. J. Immunol. 133:1090-92
198. Sanz I, Capra J. 1987. VK and JK gene segments of A/J Ars-A antibodies: Somatic recombination generates the essential arginine at the junction of the variable and joining regions. Proc. Natl. Acad. Sci. USA 84:1085-89
199. Manser T, Wysocki LJ, Margolies MN, Gefter ML. 1987. Evolution of antibody variable region structure during the immune response. Immunol. Rev. 96:141-62
200. Wysocki LJ, Gridley T, Huang S, Grandea AG 3rd, Gefter ML. 1987. Single germline VII and V kappa genes encode predominating antibody variable regions elicited in strain A mice by immunization with p-azophenylarsonate. J. Exp. Med. 166:1-11
201. Insel RA, Adderson EE, Carroll WL. 1992. The repertoire of human antibody to the Haemophilus influenzae type b capsular polysaccharide. Int. Rev. Immunol. 9:25-43
202. Akira S, Takeda K, Kaisho T. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-80
203. Underhill DM, Ozinsky A. 2002. Toll-like receptors: key mediators of microbe detection. Curr. Opin. Immunol. 14:103-10
204. Janeway CA Jr, Medzhitov R. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197-216
205. Krieg AM, Yi AK. 2000. Rescue of B cells from apoptosis by immune stimulatory CpG DNA. Springer Semin. Immunopathol. 22:55-61
206. Mackay F, Browning IL. 2002. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol. 2:465-75
207. Orsini E, Foa R. 2001. Cytokines and regulatory molecules in the pathogenesis and clinical course of B-cell chronic lymphocytic leukemia. See Ref. 277, pp. 127-59
208. Hamblin TJ, Oscier DJ, Young BJ. 1986. Autoimmunity in chronic lymphocytic leukemia. J. Clin. Pathol. 39:713-16
209. Broker BM, Klajman A, Youinou P, Jouquan J, Worman CP, et al. 1988. Chronic lymphocytic leukemic cells secrete multispecific autoantibodies. J. Autoimmun. 1:469-81
210. Sthoeger ZM, Wakai M, Tse DB, Vinciguerra VP, Allen SL, et al. 1989. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J. Exp. Med. 169:255-68
211. Borche L, Lim A, Binet JL, Dighiero G. 1990. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 76:562-69
212. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. 2001. MALT lymphomas. Hematology (Am. Soc. Hematol. Educ. Progr.):241-58
213. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, et al. 2002. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100:1215-19
214. Fu SM, Winchester RJ, Feizi T, Walzer PD, Kunkel HG. 1974. Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes. Proc. Natl. Acad. Sci. USA 71:4487-90
215. Deegan MJ, Abraham JP, Sawdy KM, Van Slyke EJ. 1984. High incidence of monoclonal antibodies in the serum and urine of chronic lymphocytic leukemia. Blood 64:1207-11
216. Qian GX, Fu SM, Solanki DL, Rai KR. 1984. Circulating monoclonal IgM proteins in B cell chronic lymphocytic leukemia: their identification, characterization and relationship to membrane IgM. J. Immunol. 133:3396-400
217. Sinclair D, Dagg JH, Mowat AM, Parrott DM, Stott DI. 1984. Serum paraproteins in chronic lymphocytic leukaemia. J. Clin. Pathol. 37:463-66
218. Fu SM, Chiorazzi N, Kunkel HG, Halper JP, Harris SR. 1978. Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. J. Exp. bled. 148:1570-78
219. Fu SM, Chiorazzi N, Kunkel HG. 1979. Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia. Immunol. Rev. 48:23-44
220. Chiorazzi N, Fu S, Montazeri G, Kunkel H, Rai K, Gee T. 1979. T cell helper defect in patients with chronic lymphocytic leukemia. J. Immunol. 122:1087-90
221. Chiorazzi N, Fu SM, Kunkel HG. 1979. Induction of human antibody responses in vitro with emphasis on allogeneic helper factors. Immunol. Rev. 45:219-41
222. Totterman TH, Nilsson K, Sundstrom C. 1980. Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature 288:176-78
223. Rubartelli A, Sitia R, Zicca A, Grossi CE, Ferrarini M. 1983. Differentiation of chronic lymphocytic leukemia cells: correlation between the synthesis and secretion of immunoglobulins and the ultrastructure of the malignant cells. Blood 62:495-504
224. Efremov DG, Ivanovski M, Batista FD, Pozzato G, Burrone OR. 1996. IgM-producing chronic lymphocytic leukemia cells undergo immunoglobulin isotype-switching without acquiring somatic mutations. J. Clin. Invest. 98:290-98
225. Fais F, Sellars B, Ghiotto F, Yan XJ, Dono M, et al. 1996. Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J. Clin. Invest. 98:1659-66
226. Garand R, Sahota SS, Avet-Loiseau H, Talmant P, Robillard N, et al. 2000. IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12. Br. J. Haematol. 109:71-80
227. Dono M, Hashimoto S, Fais F, Trejo V, Allen SL, et al. 1996. Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. Blood 87:1586-94
228. Gurrieri C, McGuire P, Zan H, Yan X-J, Cerutti A, et al. 2002. Chronic lymphocytic leukemia B cells undergo somatic hypermutation and intraclonal immunoglobulin VHDJH gene diversification. J. Exp. Med. 196:629-39
229. Albesiano E, Messmer B, Damle R, Allen SL, Kudalkar PR, et al. 2002. Activation-induced cytidine deaminase expression in chronic lymphocytic leukemia B cells. Blood 100:99a
230. Honjo T, Kinoshita K, Muramatsu M. 2002. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu. Rev. Immunol. 20:165-96
231. Wang CY, Good RA, Ammirati P, Dymbort G, Evans RL. 1980. Identification of a p69,71 complex expressed on human T cells sharing determinants with B-type chronic lymphatic leukemic cells. J. Exp. Med. 151:1539-44
232. Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G. 1982. Infrequent normal B lymphocytes express features of B-cell chronic lymphocytic leukemia. J. Exp. Med. 155:623-28
233. Zupo S, Dono M, Massara R, Taborelli G, Chiorazzi N, Ferrarini M. 1994. Expression of CD5 and CD38 by human CD5 B cells: requirement for special stimuli. Eur. J. Immunol. 24:1426-33
234. Liu YJ, Johnson GD, Gordon J, MacLennan IC. 1992. Germinal centres in T-cell-dependent antibody responses. Immunol. Today 13:17-21
235. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, et al. 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Blood 84:1361-92
236. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, et al. 1999. World Health Organization classification of neoplastic diseases of the hematopoieric and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. 17:3835-49
237. Hardy RR, Hayakawa K. 2001. B cell development pathways. Annu. Rev. Immunol. 19:595-621
238. Spencer J, Perry ME, Dunn-Walters DK. 1998. Human marginal-zone B cells. Immunol. Today 19:421-26
239. Timens W, Poppema S. 1985. Lymphocyte compartments in human spleen. An immunohistologic study in normal spleens and uninvolved spleens in Hodgkin's disease. Am. J. Pathol. 120:443-54
240. Dono M, Burgio VL, Tacchetti C, Favre A, Augliera A, et al. 1996. Subepithelial B cells in the human palatine tonsil. I. Morphologic, cytochemical and phenotypic characterization. Eur. J. Immunol. 26:2035-42
241. Dono M, Zupo S, Leanza N, Melioli G, Fogli M, et al. 2000. Heterogeneity of tonsillar subepithelial B lymphocytes, the splenic marginal zone equivalents. J. Immunol. 164:5596-604
242. O'Connor BP, Cascalho M, Noelle RJ. 2002. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J. Exp. Med. 195:737-45
243. Martin F, Kearney JF. 2002. Marginal-zone B cells. Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk. Nat. Rev. Immunol. 2:323-35
244. Amlot PL, Hayes AE. 1985. Impaired human antibody response to the thymus-independent antigen, DNP-Ficoll, after splenectomy. Implications for post-splenectomy infections. Lancet 1:1008-11
245. Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. 1989. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J. Immunol. 143:3200-6
246. Kayhty H, Karanko V, Peltola H, Makela PH. 1984. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 74:857-65
247. Kumararatne DS, MacLennan IC. 1982. The origin of marginal-zone cells. Adv. Exp. Med. Biol. 149:83-90
248. Dunn-Walters DK, Isaacson PG, Spencer J. 1995. Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells. J. Exp. Med. 182:559-66
249. Tierens A, Delabie J, Michiels L, Vandenberghe P, De Wolf-Peeters C. 1999. Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. Blood 93:226-34
250. Dunn-Walters DK, Isaacson PG, Spencer J. 1996. Sequence analysis of rearranged Ig VH genes from microdissected human Peyer's patch marginal zone B cells. Immunology 88:618-24
251. Martin F, Kearney JF. 2000. Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk. Immunity 12:39-49
252. Cariappa A, Tang M, Parng C, Nebelitskiy E, Carroll M, et al. 2001. The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity 14:603-15
253. Guinamard R, Okigaki M, Schlessinger J, Ravetch JV. 2000. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat. Immunol. 1:31-36
254. Dono M, Zupo S, Colombo M, Massara R, Gaidano GL, et al. 2003. The human marginal zone B cell. Ann. NY Acad. Sci. In press
255. Dono M, Zupo S, Augliera A, Burgio VL, Massara R, et al. 1996. Subepithelial B cells in the human palatine tonsil. II. Functional characterization. Eur. J. Immunol. 26:2043-49
256. Liu YJ, Barthelemy C, de Bouteiller O, Arpin C, Durand I, Banchereau J. 1995. Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid upregulation of B7-1 and B7-2. Immunity 2:239-48
257. Wardemann H, Boehm T, Dear N, Carsetti R. 2002. B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J. Exp. Med. 195:771-80
258. William J, Euler C, Christensen S, Shlomchik MJ. 2002. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 297:2066-70
259. Herzenberg LA. 2000. B-1 cells: the lineage question revisited. Immunol. Rev. 175:9-22
260. Martin F, Kearney JF. 2001. B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 13:195-201
261. Hayakawa K, Asano M, Shinton SA, Gui M, Allman D, et al. 1999. Positive selection of natural autoreactive B cells. Science 285:113-16
262. Macpherson AJ, Lamarre A, McCoy K, Harriman GR, Odermatt B, et al. 2001. IgA production without mu or delta chain expression in developing B cells. Nat. Immunol. 2:625-31
263. Berland R, Wortis HH. 2002. Origins and functions of B-1 cells with notes on the role of CD5. Annu. Rev. Immunol. 20:253-300
264. Martin F, Kearney JF. 2000. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol. Rev. 175:70-79
265. Fagarasan S, Honjo T. 2000. T-independent immune response: new aspects of B cell biology. Science 290:89-92
266. Nisitani S, Murakami M, Akamizu T, Okino T, Ohmori K, et al. 1997. Preferential localization of human CD5+ B cells in the peritoneal cavity. Scand. J. Immunol. 46:541-45
267. Ghia P, Caligaris-Cappio F. 2001. The origin and nature of the chronic lymphocytic leukemia lymphocyte. See Ref. 277, pp. 63-80
268. Dighiero G, Poncet P, Rouyre S, Mazie JC. 1986. Newborn Xid mice carry the genetic information for the production of natural autoantibodies against DNA, cytoskeletal proteins, and TNP. J. Immunol. 136:4000-5
269. Dighiero G, Kipps T, Schroeder HW, Chiorazzi N, Stevenson F, et al. 1996. What is the CLL B-lymphocyte? Leuk. Lymphoma 22:13-39
270. Chen X, Martin F, Forbush KA, Perlmutter RM, Kearney JF. 1997. Evidence for selection of a population of multireactive B cells into the splenic marginal zone. Int. Immunol. 9:27-41
271. Bendelac A, Bonneville M, Kearney JF. 2001. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 1:177-86
272. Li Y, Li H, Weigert M. 2002. Autoreactive B cells in the marginal zone that express dual receptors. J. Exp. Med. 195:181-88
273. Roudier J, Silverman GJ, Chen PP, Car-son DA, Kipps TJ. 1990. Intraclonal diversity in the VH genes expressed by CD5-chronic lymphocytic leukemia-producing pathologic IgM rheumatoid factor. J. Immunol. 144:1526-30
274. Korganow AS, Martin T, Weber JC, Lioure B, Lutz P, et al. 1994. Molecular analysis of rearranged VH genes during B cell chronic lymphocytic leukemia: intraclonal stability is frequent but not constant. Leuk. Lymphoma 14:55-69
275. Isobe K, Tamaru J, Uno T, Yasuda S, Aruga T, et al. 2001. Immunoglobulin heavy chain variable region (VH) genes of B cell chronic lymphocytic leukemia cells from lymph nodes show somatic mutations and intraclonal diversity irrespective of follicular dendritic cell network. Leuk. Lymphoma 42:499-506
276. Kuppers R, Klein U, Hansmann ML, Rajewsky K. 1999. Cellular origin of human B-cell lymphomas. N. Engl. J. Med. 341:1520-29
277. Dyer MJS, Oscier DG. 2002. The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. Leukemia 16:973-84
278. Messmer B, Messmer D, Allen SL, Kudalkar P, Rai KR, Chiorazzi N. 2002. Three subsets of chronic lymphocytic leukemia defined by gene expression profiles. Blood 100:378a
279. Grimaldi CM, Michael DJ, Diamond B. 2001. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J. Immunol. 167:1886-90
280. Weller S, Faili A, Garcia C, Braun MC, Le Deist FF, et al. 2001. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc. Natl. Acad. Sci. USA 98:1166-70
281. Adderson EE, Shackelford PG, Quinn A, Wilson PM, Cunningham MW, et al. 1993. Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. J. Clin. Invest. 91:2734-43
282. Adderson EE, Shackelford PG, Quinn A, Wilson PM, Carroll WL. 1993. Diversity of immunoglobulin light chain usage in the human immune response to Haemophilus influenzae type b capsular polysaccharide. Pediatr. Res. 33:307-11
283. Adderson EE, Shackelford PG, Quinn A, Carroll WL. 1991. Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. J. Immunol. 147:1667-74
284. Silverman GJ, Lucas AH. 1991. Variable region diversity in human circulating antibodies specific for the capsular polysaccharide of Haemophilus influenzae type b. Preferential usage of two types of VH3 heavy chains. J. Clin. Invest. 88:911-20
285. Cheson BD, ed. 2001. Chronic Lymphoid Leukemias. New York: Marcel Dekker. 2nd ed.